iRadimed Corporation
IRMD Healthcare Medical Devices
iRadimed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $83.8 million, up 14.4% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 8.89% and free cash flow grew 11.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow IRMD
iRadimed Corporation (IRMD) Altman Z-score
iRadimed Corporation's Altman Z-score for fiscal 2025 is 55.62, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 55.62 | 16.18 |
| FY2024 | 39.44 | 19.27 |
| FY2023 | 20.17 | (0.80) |
| FY2022 | 20.98 | (13.69) |
| FY2021 | 34.66 | 15.39 |
| FY2020 | 19.28 | 2.43 |
| FY2019 | 16.85 | (10.25) |
| FY2018 | 27.10 | 8.81 |
| FY2017 | 18.29 | 1.14 |
| FY2016 | 17.14 | (42.28) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.65 | — | 0.78 | |
| Retained earnings / total assets | 0.59 | — | 0.83 | |
| EBIT / total assets | 0.24 | — | 0.79 | |
| Market value of equity / total liabilities | 87.41 | — | 52.45 | |
| Sales / total assets | 0.77 | — | 0.77 | |
| Altman Z-score | Safe zone | 55.62 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 14.84 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| IRMD iRadimed Corporation | 55.6× |
| CBLL CeriBell, Inc. compare | 10.8× |
| PRCT PROCEPT BioRobotics Corporation compare | 6.4× |
| AORT Artivion, Inc. compare | 3.7× |
| BVS Bioventus Inc. compare | 1.3× |
| LMRI Lumexa Imaging Holdings, Inc. compare | 1.0× |
| IART Integra LifeSciences Holdings Corporation compare | 0.6× |
| TNDM Tandem Diabetes Care, Inc. compare | 0.2× |
| ENOV Enovis Corporation compare | −0.3× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets